For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Tafamidis and Attruby represents a genuine breakthrough . These groundbreaking therapies protect the transthyretin protein, halting its destructive build-up and alleviating the bur